The landscape of drug development is undergoing a significant transformation, particularly in India, where Global Capability Centres (GCCs) are leading the charge. By leveraging advanced technologies such as artificial intelligence (AI), automation, and analytics, these centres are effectively shortening the time it takes to bring new drugs to market while simultaneously reducing costs.
The Rise of GCCs in India
India has established itself as a hub for Healthcare and Life Sciences GCCs, boasting over 150 such centres. These facilities encompass a wide range of functions including research and development (R&D), Global Business Services, Global Shared Services, and Centres of Excellence. The strategic establishment of these centres is not just a trend; it signifies a robust commitment to enhancing the pharmaceutical landscape.
Accelerating Drug Development Timelines
A recent report highlights the remarkable capabilities of India’s GCCs in cutting drug development timelines by one to two years. Traditionally, the drug development process spanned 10 to 15 years. However, with the end-to-end integration of AI and automation, this timeline is now compressed to between 9 to 13 years. This is a pivotal shift, as it allows for quicker access to essential medications and therapies for patients in need.
Cost Efficiency in R&D
The financial implications of these advancements are equally compelling. The report indicates a 5% reduction in R&D-to-launch costs, driven primarily by the efficiencies gained through technology. Previously, the costs associated with bringing a drug to market ranged from 20% to 30% of the overall budget; this has now been reduced to 15% to 25%. The financial burden on pharmaceutical companies is lightened, enabling them to allocate resources toward further innovation.
Enhancing R&D Processes
GCCs are fundamentally changing the R&D landscape by accelerating processes such as target identification, protein modelling, and compound screening. These advancements are estimated to cut early-stage timelines by 5 to 6 years. In the realm of clinical trials, AI is revolutionizing patient recruitment and trial design, as well as enabling real-time analytics. These innovations are not just about speed; they are also improving success rates, fostering a more reliable path from research to market.
The Future of GCCs
As the GCC model evolves, its next phase will hinge on contextual business understanding and core sector knowledge. Shalini Pillay, a leader in the GCC space at KPMG India, emphasizes that the integration of emerging technologies, particularly Generative AI, will tackle sector-specific challenges and maximize return on investment. This evolution is crucial for the sustainable growth of the pharmaceutical industry.
Innovation Hubs
GCCs serve as innovation hubs, focused on refining data structures and integrating technology across the value chain. Their investment in techno-functional capabilities and the collaboration with the broader ecosystem are key elements that will drive research and innovation forward. This interconnected approach ensures that the industry adapts swiftly to new challenges and opportunities, enhancing its overall resilience.
Conclusion
India’s GCCs are not merely facilitators of drug development; they are game-changers that redefine the pharmaceutical landscape. By compressing timelines and cutting costs through advanced technologies, they pave the way for quicker access to life-saving treatments. As these centres continue to evolve, they will play an indispensable role in shaping the future of drug development and healthcare innovation.
- Key Takeaways:
- GCCs in India are reducing drug development timelines from 10-15 years to 9-13 years.
- R&D-to-launch costs have decreased by 5%, enhancing financial efficiency.
- AI and automation are streamlining early-stage R&D processes, cutting timelines by up to 6 years.
- The evolution of GCCs is driven by contextual business knowledge and leveraging emerging technologies.
- These centres are vital innovation hubs that enhance the overall pharmaceutical ecosystem.
Read more → www.thehindubusinessline.com